|Day Low/High||95.24 / 96.80|
|52 Wk Low/High||88.32 / 147.17|
Celgene Corporation (NASDAQ:CELG) announced that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had failed at least one...
Celgene Corporation (NASDAQ: CELG) today announced the election of John Weiland to its Board of Directors.
I continue to deploy some of the 'dry powder' into the market after its recent hiccup.
Celgene Corporation (NASDAQ: CELG) today announced the Company's Board of Directors authorized the repurchase of an additional $5 billion of the Company's common stock.
Wow. Corporate America is sitting on massive amounts of cash that could be unleashed on deals, according to new research from Citi.
In this tape, weakness may just be a sign of rest and better times to come.
Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of four series of senior unsecured notes for an aggregate principal amount of $4.
A steeper fall might cause both buyers and sellers to re-think potential deals, but so far that doesn't seem to be the case yet.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
Celgene Corporation (NASDAQ:CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and...
Celgene Corporation (NASDAQ:CELG) today announced that the Phase III, randomized, open-label, international clinical study, OPTIMISMM, achieved its primary endpoint, showing a statistically significant and clinically...
Vertex Pharmaceuticals, Amgen and Johnson and Johnson were among the big movers in the biotech and pharmaceutical sectors.
Celgene Corporation (NASDAQ:CELG) today announced that its wholly-owned subsidiary, Blue Magpie Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Juno...
Celgene Corporation (NASDAQ: CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company.
The biotech sector has seen a big rally, but there are still opportunities.
Celgene Corporation (NASDAQ:CELG) today announced that Executive Chairman Bob Hugin has decided to retire from Celgene after 19 years of service and to step down from the Celgene Board of Directors, effective February 5,...
Here's what you need to know now for Thursday, Jan. 25
Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.
The biopharmaceutical giant's top executive says the company will continue to aggressively invest in R&D and deploy capital to acquire or license assets.
U.S. stock futures rise as the dollar plunges to a fresh three-year low. Caterpillar, Intel and 3M leading the earnings calendar.
Celgene Corporation (NASDAQ:CELG) reported operating results for the fourth quarter and full year of 2017.
Consumer spending should be more than solid given wage increases.
Is there anything that could derail the stock market's momentum this year? The answer is probably not, suggests Bank of America.
Here's what you need to know now for Monday, Jan. 22.
A flurry of high-priced merger-and-acquisition activity explains the move in Allergan.
Stocks hit fresh records on Monday after a deal is reached to end the three-day government shutdown.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.